Search

Displaying results 3691 - 3700 of 3732 in total
  1. Drug

    Hippuric acid

    go.drugbank.com/drugs/DB16842
    Experimental

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  2. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    Levacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid leucine. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo. Observational studies in patients with Ni...

    Categories: P-glycoprotein inhibitors
  3. Drug

    Sepantronium

    go.drugbank.com/drugs/DB17062
    Investigational

    Sepantronium is a compound that suppresses survivin expression in a dose and time-dependent manner, and causes broad-range apoptosis.

    Categories: P-glycoprotein substrates
  4. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2...

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  5. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. Similar to the previously developed tafamidis, acoramidis is used to stabilize TTR in its tetrameric form, preventing the formatio...

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in the majority of infant acute lymph...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  7. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    It is targeted against ROS1, including resistant mutant forms, and shows some inhibitor activity against tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC.

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  8. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-produc...

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    Elinzanetant is a non-hormonal, selective, dual neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

    Categories: Substance P/Neurokinin-1 Receptor Antagonist, Cytochrome P-450 CYP3A Inhibitors